Orphan drugs threatened with illegal hurdle, warns German pharma association
This article was originally published in Scrip
The BPI, an association representing mainly innovative German pharma firms, is concerned that the G-BA, the joint federal healthcare committee, will require some orphan drugs to undergo the new rapid benefit assessment that is replacing free pricing for new drugs. Germany's controversial new healthcare law (the Amnog) had seemingly exempted most orphan drugs from the assessment, and Dr Alexander Natz, head of the BPI's Brussels office, told Scrip that a legal battle could ensue as BPI believed that the actions G-BA was proposing would be illegal.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.